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Abstract 
Background: Myocardial fibrosis plays a key role in the development of adverse left ventricular 
remodeling after myocardial infarction (MI). This study aimed to determine whether the circulating 
levels of BNP, collagen peptides, and galectin-3 are associated with diastolic function evolution (both 
deterioration and improvement) at 1-year after an anterior MI. 
Methods: The REVE-2 is a prospective multicenter study including 246 patients with a first anterior 
Q-wave MI. Echocardiographic assessment was performed at hospital discharge and ±1-year after MI. 
BNP, Galectin-3 and collagen peptides were measured ±1-month after MI. Left ventricular diastolic 
dysfunction (DD) was defined according to the presence of at least 2 criteria of echocardiographic 
parameters: septal e’<8 cm/s, lateral e’<10 cm/s and left atrial volume ≥34 mL/m2. 
Results: At baseline 87 (35.4%) patients had normal diastolic function and 159 (64.6%) patients had 
diastolic dysfunction. Follow-up of 61 patients among the 87 patients with normal diastolic function at 
baseline showed that 22 patients (36%) developed DD at 1-year post-MI. The  circulating levels of 
PIIINP>6 mg/l (Odds Ratio, OR=5.29; 95%CI=1.05-26.66; p=0.044), Galectin-3>13 μg/l (OR=5.99; 
95%CI=1.18-30.45; p=0.031), and BNP>82 ng/l (OR=10.25; 95%CI=2.36-44.50; p=0.002) quantified 
at 1-month post-MI were independently associated with 1-year DD. Follow-up of the 137 patients with 
DD at baseline among the 159 patients showed that 36 patients (26%) had a normalized diastolic 
function at 1-year post-MI. Patients with a BNP>82 ng/l were less likely to improve diastolic function 
(OR=0.06; 95%CI=0.01-0.28; p=0.0003). 
Conclusions. The present study suggests that circulating levels of PIIINP, Galectin-3 and BNP may be 
independently associated with new-onset DD in post-MI patients.  
 
Key-words: Myocardial infarction; diastolic dysfunction; cardiac remodeling; Galectin-3; collagen 
peptides.  
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Introduction 
Cardiac remodeling after a myocardial infarction (MI) is an important prognostic and 
treatment response indicator
1
. Declines in post-MI events have been observed in patients with heart 
failure and reduced ejection fraction (HF-REF) but not for those with heart failure and preserved 
ejection fraction (HF-PEF)
2
, suggesting that new diagnostic strategies and early identification of 
patients prone to develop HF-PEF are required. In HF-PEF patients, diastolic dysfunction (DD) has 
been described as a marker of impaired cardiac remodeling and has also been associated with HF-PEF 
onset and adverse prognosis
3, 4
.  
Myocardial fibrosis has been identified as one of the major pathways leading to adverse 
remodeling and diastolic dysfunction after acute MI
5-8
. In subjects undergoing cardiac resonance 
imaging (excluding those referred for severe valvulopathy, congenital heart disease, pericarditis or 
pericardial disease), those with normal diastolic function exhibited no or minimal fibrosis. In contrast, 
the majority of patients with abnormal diastolic function indices exhibited substantial fibrosis 
regardless of underlying cause
7
. We previously reported that a ratio≤1 of amino-terminal propeptide of 
type III procollagen to type 1 collagen telopeptide (PIIINP/ICTP) at 1-month was associated with a 
>20% increase in LV end-diastolic volume at 1-year after a Q-wave anterior MI
9
. However, an 
increase in LV end-diastolic volume may be misleading in the setting of preserved LVEF. Indeed, in 
this context, the “fibrosis burden” may actually lead to a reduction in LV end-diastolic volume and 
potentially increase the LVEF in the setting of a stable stroke volume
10,8
. In a model of age-associated 
adverse cardiac remodeling, the LV end-diastolic volume was shown to markedly decrease with age, 
despite altered strain patterns reflecting both systolic and diastolic dysfunction
11
, suggesting that DD is 
a better reflection of adverse remodeling compared to an increase in LV end-diastolic volume in the 
setting of a preserved EF (LVEF may actually increase in this context)
10-12
. Despite the lack of 
definitive consensus for the definition of DD
13
, the echocardiographic parameters used to assess DD 
(such as septal e`, lateral e`, and left atrial volume) have been shown to be associated with natriuretic 
peptides and long-term outcomes
14
. Biomarkers such as brain natriuretic peptide (BNP) and Galectin-3 
(Gal-3) have also been studied in the acute MI setting and have been associated with adverse 
remodeling and prognosis
6, 15
. 
The aim of the present study was to assess whether BNP, Gal-3, PIIINP, ICTP and 
PIIINP/ICTP ratio measured at 1-month after an anterior Q-wave MI may be associated with LV 
remodeling at 1-year as assessed by the evolution in LV diastolic function.  
 
Methods 
Study population 
The design and entry criteria of the REVE-2 study have been previously published
9, 16
. In 
short, the REVE-2 was a prospective multicenter observational study designed to analyze the 
association of circulating biomarkers with LV remodeling in patients with a first anterior wall Q-wave 
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MI
16
. Patients were enrolled from February 2006 to September 2008. Main inclusion criteria were 
hospitalization within 24h after symptom onset and a pre-discharge echocardiogram showing at least 3 
akinetic LV segments in the infarct zone. Exclusion criteria were inadequate quality of the 
echocardiographic image, life-limiting noncardiac disease, significant valvular disease or a prior Q-
wave MI.  
The institutional Ethics Committee (Centre Hospitalier Universitaire de Lille) approved the 
study, and written informed consent was obtained from all patients.  
No clinical trials.gov number was assigned to this study since it was initiated in 2006. 
Echocardiographic assessment  
Serial echocardiographic studies were performed at hospital discharge (day 3 to 7) and 12 
months after initial MI. A standard echocardiographic imaging protocol was used, with apical 4- and 
2-chamber views; 2D echocardiograms of the LV short axis were recorded from the left parasternal 
region at 3 levels: the mitral valve, the mid papillary muscle and the apex. All echocardiograms were 
analyzed at the Lille Core Echo Laboratory (Lille, France), as previously described
17
. Diastolic 
dysfunction was defined according to the 2009 recommendations of the American Society of 
Echocardiography and the Committee of the European Association of Echocardiography
18
. Patients 
with at least 2 of the following parameters, namely 1) septal e` <8 cm/s; 2) lateral e` <10 cm/s; and 3) 
left atrial volume index (LAVi) ≥34 ml/m2, were considered to have DD, i.e. the primary outcome of 
the present post-hoc study. 
Biomarkers 
All biomarkers were measured in plasma and serum samples obtained at 1 month after 
myocardial infarction, as previously described
9
. Plasma and serum were collected in glass tubes and 
processed within 2 hours. Samples were stored at -80°C. Samples underwent no more than 2 
freeze/thaw cycles before analysis in a core laboratory (Lille, France for brain natriuretic peptide 
(BNP) and Nancy, France for collagen peptides and Galectin-3). BNP was measured with a fully 
automated 2-site sandwich immunoassay on an Advia Centaur analyzer (Siemens Diagnostic, Zurich, 
Switzerland). The lowest measurable concentration with this assay with a ≤ 20% coefficient of 
variation is 2.5 ng/l. Radioimmunoassay kits (Orion Diagnostica, Espoo, Finland) were used for 
determination of serum collagen peptide concentrations: PINP (aminoterminal propeptide of type I 
procollagen; reference range: 22 to 87 and 19 to 83 mg/l in men and women, respectively); PIIINP 
(aminoterminal propeptide of type III procollagen; reference range: 2.3 to 6.4 mg/l); and ICTP (type 1 
collagen telopeptide; reference range: 3.2 to 3.5 mg/l). The inter-assay variations were <9.8%
19
. 
Determination of Gal-3 was assessed using enzyme-linked immuno-sorbent assay (ELISA) kits (BGM 
Galectin-3 assay; BG Medicine, Inc., Waltham, MA, USA). The minimum sensitivity was 0.96 μg/l. 
Normal serum ranges were provided by the assay manufacturer, on the basis of apparently healthy 
volunteers. The 90th, 95th, and 97.5th percentiles of the normal reference interval were 17.6, 20.3 and 
22.1 μg/l, respectively. Intra- and interassay variations were < 8% and 10%20. Estimated glomerular 
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filtration rate (eGFR) was computed using the 4-variable MDRD (Modification of Diet in Renal 
Disease) Study formula
21
. 
Statistical analysis 
Continuous variables are expressed as mean ± standard deviation (SD) and median 
(percentile25-75). Categorical variables are expressed as absolute numbers and proportions (%).  
Factors associated with DD were first identified using univariable followed by multivariable 
stepwise backward conditional logistic regression. The covariates inserted in the models were 
identified among patient characteristics listed in Table 1 with a p-value <0.1. Efforts were made to 
respect the “rule of thumb” of 1 variable for each 10 events22. Linearity was assessed by plotting the β-
estimates vs. mean according to quintiles of the studied variable and by using restricted cubic splines. 
Variables were then categorized in order to obtain log-linearity corresponding to median for PIIINP, 
ICTP, PIIINP/ICTP, BNP and Galectin-3. Logistic regression data are presented as odds ratios (OR) 
and respective 95% confidence intervals (95%CI).  
All analyses were performed using SAS 9.2 software (SAS Institute, Cary, NC, USA). The 
two-tailed significance level was set at p <0.05. 
 
Results 
Patient characteristics 
A total of 246 patients were included in the REVE-2 study and 198 patients (80.5%) were 
analyzed for a follow-up of diastolic function at 1-year post-MI. Among the 198 patients, 87 patients 
(35.4%) had a normal diastolic function at baseline (Septal e’ median=8.5 [Q1-Q3=7.0-9.10], Lateral 
e’ =10.0 [9.2-12.0] and LAV =19.4 [16.7-22.5]) and 159 patients (64.6%) had diastolic dysfunction 
(DD) (Septal e’ =5.7 [4.7-6.6], Lateral e’ =7.0 [5.6-8.3] and LAV =19.8 [16.0-24.4]). The two 
subgroups of patients (normal diastolic function vs. DD) were analyzed for evolution of LV diastolic 
function 1-year post-MI as described in the flowchart (Figure 1). A total of 26 patients (29.8%) with 
normal diastolic function and 22 patients (20.1%) in the DD subgroup were not analyzed due to 
missing data (n=42) or low quality (n=6) for the parameters required to evaluate diastolic dysfunction.  
Among the 61 patients without DD at baseline, 22 (36%) developed DD at 1-year post-MI, 
and 39 (64%) remained without DD. Compared to patients without DD at 1-year, those with “new-
onset” DD were older (55±14 vs. 48±13 years; p=0.043), had higher diastolic blood pressure 
(66.0±12.2 vs. 59.1±8.4 mmHg; p=0.013), hypertension history (45% vs. 21%; p=0.04), and exhibited 
higher BNP (median =185 [percentile25-75 =63-321] vs. 43 [27-66] ng/l, p =0.0002) and Gal-3 (18.3 
[12.7-22.2] vs. 8.3 [3.9-15.8] μg/l, p =0.002) concentrations at 1month post-MI. LVEF was similar 
between the two groups (51%±10% vs. 52%±7%, p=0.45). Table 1. Among the 137 patients with DD 
at baseline, 36 (26%) normalized diastolic function at 1-year post-MI, and 101 (74%) remained with 
DD. Compared to patients that remained with DD at 1-year, those who improved their diastolic 
function were younger (53±11 vs. 62±12 years; p=0.0002) and had higher eGFR (88±21 vs. 
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78±19 ml/min/.73m
2
; p=0.011). Supplemental Table 1. 
Association of the studied biomarkers with diastolic function evolution at 1-year 
 In patients without DD at baseline, circulating levels of PIIINP >6 mg/l, Gal-3 >13 μg/l, and 
BNP >82 ng/l were associated with the development of DD at 1-year post-MI. These associations 
remained significant after adjusting for eGFR and hypertension: adjusted OR (95%CI)=5.29 (1.05 - 
26.66) for PIIINP; =5.99 (1.18 - 30.45) for Gal-3; and =10.25 (2.36 - 44.50) for BNP. Table 2. 
Patients with BNP >82 ng/l were less likely to normalize diastolic function at 1-year post-MI: adjusted 
OR (95%CI)=0.06 (0.01 - 0.28). Supplemental Table 2. The studied biomarkers were poorly 
correlated and did not present significant collinearity in the multivariable models. Supplemental 
Table 3. There were no significant medication changes at 1-year that could potentially be associated 
with biomarker changes. Supplemental Table 4. 
Correlation between the studied biomarkers and diastolic function parameters 
 Certain echocardiographic parameters of diastolic function were correlated with circulating 
biomarkers. In the global REVE-2 population, BNP was significantly correlated with lateral e`, septal 
e`, and left atrial volume (the higher the BNP level, the lower/worse the lateral e`, septal e`, and the 
higher the left atrial volume); PIIINP was correlated with septal e` (the higher the PIIINP level, the 
lower/worse the septal e`); and Gal-3 was correlated with lateral e` and septal e` (the higher the Gal-3 
level, the lower/worse the lateral e` and septal e`). Figure 2. 
 
Discussion 
The present study shows that circulating levels of PIIINP, Gal-3, and BNP measured at 1-
month post-MI may be associated with the development of DD 1-year after MI in patients with normal 
diastolic function at baseline. On the other hand, patients with DD and higher BNP levels are less 
likely to recover normal diastolic function, but PIIINP and Gal-3 were not associated with DD 
normalization. These results may help in identifying a subset of patients more prone to develop 
adverse LV remodeling and DD in whom tailored anti-remodeling and preventive strategies could be 
tested.  
 The present findings confirm that myocardial fibrosis turnover is critical after a first anterior 
wall MI, playing a key role in adverse remodeling and DD development. 
 In the post-MI setting, time-dependent damage to both myocytes and extracellular matrix 
(ECM) occurs in the infarct zone. This acute damage is followed by gradual repair with fibrosis. The 
non-infarct zone exhibits reactive hypertrophy, interstitial fibrosis and increased collagen, potentially 
leading to cardiac dysfunction
23, 24
.  Myocardial fibrosis may represent a major pathway leading to 
adverse remodeling, cardiac dysfunction and worse prognosis
25, 26
. Thus, identifying patients more 
prone to adverse remodeling and DD may help clinicians in tailoring treatments with anti-adverse 
remodeling properties
6, 27, 28
. Whether this strategy improves outcomes in patients without systolic 
dysfunction or symptomatic heart failure is yet to be determined
27, 28
.  
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 Natriuretic peptides, such as BNP, are produced by cardiomyocytes and may be increased by 
cardiac and atrial stretch, and also by other factors, such as renal impairment or atrial fibrillation
29
. 
BNP was positively associated with DD onset and negatively associated with DD improvement at 1-
year. Additionally, higher BNP was associated with lower lateral e`, septal e`, and increased left atrial 
volume, suggesting that both diastolic impairment and congestion may lead to BNP augmentation, as 
previously reported
30, 31
. 
Serum PIIINP has been found to be correlated with myocardial collagen type III in HF 
patients of ischemic etiology and idiopathic dilated cardiomyopathy (DCM)
32, 33
. Furthermore, higher 
PIIINP has been associated with insulin resistance and adverse lipid profile in obese patients without 
overt cardiovascular diseases
34
 and associated with DD in patients with abdominal obesity
35
.  In the 
present study, higher PIIINP was associated with a lower septal e` supporting the association of this 
biomarker with DD as reported in other populations
35, 36
. Higher PIIINP also trended to be associated 
with increased left atrial volume, but showed no association with lateral e` in the present study.   
Collagen scar formation after acute MI causing LV systolic dysfunction can also be quantified by 
serum PIIINP concentrations
37
. In patients with DCM, the reduction in myocardial collagen as a result 
of spironolactone treatment is also accompanied by a significant reduction in PIIINP serum levels
32
. In 
post-MI patients with systolic dysfunction (findings from the Eplerenone Post–Acute Myocardial 
Infarction Heart Failure Efficacy and Survival Study: EPHESUS)
26
, eplerenone treatment also 
consistently reduced PIIINP levels. In 134 patients with acute anterior STEMI, a strategy of early 
aldosterone blockade with intravenous potassium canrenoate (the active metabolite of spironolactone) 
improved LVEF and reduced LV end-diastolic volume in comparison to controls. In the present study, 
cardiac aldosterone extraction was suppressed and plasma PIIINP levels were also significantly 
reduced in the aldosterone antagonist group
38
. In a subanalysis of the REMINDER trial which 
included patients with STEMI without heart failure or systolic dysfunction, eplerenone was also found 
to reduce serum PIIINP levels when the latter were above the median of 3.9 ng/mL
6
.  
Gal-3 is a ubiquitous beta-galactoside-binding animal lectin present in the tissue micro-
environment (e.g., fibroblasts, macrophages, myocytes and renal cells) and may be extracellular, 
cytoplasmic or nuclear. These properties make great flexibility on Gal-3 as a modulator of numerous 
biological systems including inflammation and collagen deposition by fibroblasts that is likely 
upregulated by the renin-angiotensin-aldosterone system (RAAS)
39-42
, although its direct correlation 
with  the extent of cardiac fibrosis was found to be lacking in human heart failure of hypertensive 
origin  in one study
43
. Nonetheless, experimental models suggest that blocking Gal-3 pathways may 
attenuate cardiac fibrosis, vascular remodeling, LV dysfunction and heart failure onset
44, 45
. In this 
study, higher Gal-3 levels were associated with lower lateral e` and septal e`, suggesting that Gal-3 
may also be related to diastolic dysfunction independently of increased congestion
46, 47
. 
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Reduced systemic concentrations of ICTP may reflect reduced collagen type I fiber 
degradation by MMP-1 given that high lysyl oxidase-mediated cross-linking increases the resistance 
of the fiber to MMP-1 proteolysis
48
. In the present study, ICTP was not associated with 1-year DD. 
Altogether, in patients with non-complicated MI (≈70% of patients with Killip class <2, mean 
CPK peak ≈3000UI/l, and mean LV ejection fraction ≈50%) higher BNP, PIIINP, and Gal-3 were 
associated herein with the development of DD at 1-year post-MI. These biomarkers were correlated 
with DD echocardiographic parameters. The above findings may help to tailor therapeutic decisions 
(such as MRA introduction in a dedicated trial) and in the early identification of patients more prone 
to develop DD.   
 
Study limitations 
Several limitations should be acknowledged in the present study. First, this is a secondary 
non-prespecified analysis of an observational study, hence causality cannot be ascertained. Second, 
few patients (n=22) developed “new-onset” DD, hence the models developed herein lack accuracy and 
precision. Moreover, the adjustment on more than 2 variables (1 for each 10 “outcome events”) may 
be questionable as proposed by some authorities, hence we could not adjust on full models considering 
for example age, gender, diabetes and echocardiographic parameters because it provided largely 
inaccurate results
22
. These findings should thus be regarded as hypothesis-generating and should be 
confirmed in other cohorts. Third, while echocardiographic assessment of DD remains a matter of 
debate, the definition used for this analysis has nonetheless been shown to be reproducible and easily 
assessible
13
. Fourth, the biomarkers herein were measured at 1-month post-MI, as already reported
9, 16
, 
hence they do not reflect the acute event kinetics but may better reflect cardiac remodeling in the 
short-term post-MI phase.  Fifth, the echocardiographic and biomarker assessment was not performed 
simultaneously, hence the correlation between the biomarker levels and echocardiographic parameters 
is sub-optimal. Sixth, this study aimed to show associations with DD status and not to subclassify 
patients with DD in grades (1, 2 or 3) for which purpose the present sample is largely underpowered 
(DD n= 22). Seventh, it should be noted that the studied biomarkers were associated with different DD 
parameters: BNP with lower lateral e`, septal e`, and increased LAVi; PIIIN with a lower septal e` 
only; and Gal-3 with lower lateral e` and septal e`, but not LAVi. These findings should be interpreted 
with caution, because neither cardiac MRI nor echocardiographic strain are available to identify 
cardiac regions with potentially different fibrosis patterns. Furthermore, the outcome of interest was 
the onset of DD for which all these biomarkers were independently associated. Eight, this study did 
not incorporate magnetic resonance imaging which could have provided a better assessment of 
myocardial “fibrosis”. Finally, the low event rate (≈4%) does not allow ascertaining hard outcome 
associations.  
 
Conclusions 
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The present study suggests that PIIINP, Galectin-3 and BNP may be independently associated 
with new-onset diastolic dysfunction in post-anterior MI patients. Moreover, patients with higher 
baseline BNP may be less likely to recover normal diastolic function but PIIINP and Galectin-3 were 
not associated with diastolic dysfunction recovery. 
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